TABLE 2.
Alteration | Type | Chromosome Locus | Estimated Frequency | References |
---|---|---|---|---|
IGF2 | Loss of heterozygosity | 11p15.5 | 65% | 18 |
NRAS | Point mutation | Chr1:115256530 Chr1:115258745 |
7.5% | 18 |
KRAS | Point mutation | Chr12:25398284 Chr12:25398281 |
4% | 18 |
HRAS | Point mutation | Chr11:534289 | 3% | 18 |
NF1 | Point mutation | Multiple | 3.4% | 18 |
PIK3CA | Point mutation | Chr3:178952084-178952085 Chr3:178936094-178936096 |
5.4% | 18, 29 |
FBXW7 | Point mutation | Chr4:153247287 Chr4:153249456 Chr4:153251905 |
4.8% | 18 |
FGFR4 | Point mutation | Chr5:176522551 | 9.3% | 30 |
BCOR | Point mutation/indel | Multiple | 5.4% | 18 |
CTNNB1 | Point mutation | Chr3:41266101 Chr3:41266124 |
2% | 18, 29 |
MYOD1 | Point mutation | p.Leu122Arg | 10% of ERMS | 20, 31 |
MDM2 | Amplification | 12q15 | 10% | 32 |
Aneuploidy | Chromosome gain | Typically 2, 7, 8, 11, 13 | Common | 18 |
Chromosome loss | Typically 1p, 9, 16 | Common | 18 |
ERMS, embryonal rhabdomyosarcoma; indel, insertion/deletion.